research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
Search
for
Sort by
Research
30-60 / 1000+ results 
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
research The Trichoscopy Derived Sinclair Scale: Enhancing visual assessment through quantitative trichoscopy
The Trichoscopy Derived Sinclair Scale offers a more accurate and reliable way to measure hair loss severity than the traditional visual method.
research Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients
Trichoscopy helps better understand and manage alopecia areata, improving patient outcomes.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Development and initial validation of a modified Sinclair scale for female pattern hair loss in men
New scale reliably assesses male hair loss with female pattern.
research Toward a Diagnostic Score in Cushing's Syndrome
The document suggests creating a validated score to diagnose Cushing's Syndrome and considers plasma steroid profiling as a simpler diagnostic method.
research Low quality of life and high HSS‐29 scores reflect the risk of loss to follow‐up: a study in patients with androgenetic alopecia
Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.
research Quantitative evaluation of carcinosin as an individualized remedy in pediatric alopecia areata using salt score and ludwig hair loss scales: A case report
Carcinosin, a homeopathic remedy, helped a young girl with alopecia areata regrow hair and reduce psychological symptoms.
research SARS‐CoV‐2‐induced telogen effluvium: a multicentric study
COVID-19 infection may cause significant hair loss, but full hair recovery is likely without special treatment.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Hair evaluation methods: Merits and demerits
Different hair evaluation methods have their own pros and cons, and using multiple methods together is best for accurate hair loss diagnosis and tracking.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers
Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.
research Therapeutic Efficacy of Combination Therapy Using Oral Cyclosporine with a Dietary Supplement (Pantogar®) in Twenty-Nail Dystrophy
Oral cyclosporine combined with Pantogar® effectively treats twenty-nail dystrophy.
research Prevalence of hair shedding among women
About 40% of women without hair loss and 60% with hair loss experience a lot of hair shedding, especially those under 50 with long hair.
research Diagnostik und Therapie der kutanen Androgenisierung im klimakterischen Übergang sowie in der Peri- und Postmenopause: Hirsutismus und Alopezie
Hirsutism and alopecia during menopause can be diagnosed and treated with specific hormonal and topical therapies.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.